ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.
Sakamoto S, Sato K, Takita Y, Izumiya Y, Kumagai N, Sudo K, Hasegawa Y, Yokota H, Akamine Y, Okuda Y, Asano M, Takeda M, Sano M, Miura M, Nakayama K.
Sakamoto S, et al. Among authors: okuda y.
Invest New Drugs. 2020 Dec;38(6):1687-1695. doi: 10.1007/s10637-020-00946-x. Epub 2020 May 20.
Invest New Drugs. 2020.
PMID: 32436059